Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma

Table 2 Comparison between LRFA and TACE treatment groups in mortality, complication, and recurrence rates

	LRFA		TACE		P value
	(n = 40)		(n = 20)
One-month mortalitya	1	(2.5%)	1	(5%)
Major complications: total	7	(17.5%)	9	(45%)	< 0.05
Hepatic failureb	3		3
Pulmonary embolism	0		1
Stroke	0		1
UGIc bleeding	2		2
Pneumonia	1		0
Refractory ascites	1		2
Minor complications: total	7	(17.5%)	7	(35%)
Pneumothorax	3		0
Wound infection	2		0
Burns	2		0
Post embolization syndromed	0		7
Local recurrence rate
One year	12		7
Two years	19		11

^aOne-month mortality,

^bHepatic failure: readmission due to chronic hepatic failure within three months after procedure,

^cUGI: upper gastrointestinal tract.

^dPost embolization syn-dromes included fever, pain, nausea, vomiting, leukocytosis and adynamic ileus.